Economic evaluation and end-stage renal disease: From basics to bedside

被引:28
作者
Manns, BJ
Taub, KJ
Donaldson, C
机构
[1] Univ Calgary, Dept Med, Div Nephrol, Calgary, AB, Canada
[2] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada
[3] Univ Calgary, Dept Econ, Calgary, AB, Canada
关键词
economic evaluation; end-stage renal disease (ESRD); kidney failure; dialysis; health economics; cost-effectiveness; cost analysis; cost utility; review;
D O I
10.1053/ajkd.2000.8235
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Economic evaluation is the comparative analysis of alternative health care interventions in terms of their relative costs (resource use) and effectiveness (health effects). High-quality studies of economic evaluation have been increasingly published in medical journals and read by clinicians, although publication of these studies in nephrology journals has been a more recent phenomenon. This article shows how the basic principles of economics can be applied to health care through the use of economic evaluation. Different types of economic evaluation are discussed, and pitfalls common to such studies are identified. A simple framework is introduced that can be used to interpret the results of economic evaluations. Using this framework, selected therapies for patients with end-stage renal disease (ESRD) are categorized to highlight therapies that are very efficient, encourage their use, and draw attention to therapies in current use that are less effective and more expensive (ie, less efficient) than alternative therapy. Using examples pertinent to care of the patient with ESRD, we show how economic evaluation can be used to link medical outcomes, quality of life, and costs in a common index for multiple therapies with disparate outcome measures. This article highlights the need for clinical studies and economic evaluations of therapies in ESRD for which the effects of the therapy on health outcomes and/or costs are unknown. (C) 2000 by the National Kidney Foundation, Inc.
引用
收藏
页码:12 / 28
页数:17
相关论文
共 66 条
[1]  
[Anonymous], 1991, JAMA, V265, P3255
[2]  
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI [10.1001/archinte.1997.00440420033005, DOI 10.1001/ARCHINTE.1997.00440420033005]
[3]   The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].
Besarab, A ;
Bolton, WK ;
Browne, JK ;
Egrie, JC ;
Nissenson, AR ;
Okamoto, DM ;
Schwab, SJ ;
Goodkin, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590
[4]  
BLOEMBERGEN WE, 1995, J AM SOC NEPHROL, V6, P177
[5]   COMPARATIVE COST-BENEFIT-ANALYSIS IN EARLY AND LATE DIALYSIS [J].
BONOMINI, V ;
BALDRATI, L ;
STEFONI, S .
NEPHRON, 1983, 33 (01) :1-4
[6]   Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes [J].
Bostom, AG ;
Lathrop, L .
KIDNEY INTERNATIONAL, 1997, 52 (01) :10-20
[7]   The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass [J].
Brulez, HFH ;
van Guldener, C ;
Donker, AJM ;
ter Wee, PM .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (01) :154-159
[8]   The west of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin [J].
Caro, J ;
Klittich, W ;
McGuire, A ;
Ford, J ;
Norrie, J ;
Pettitt, D ;
McMurray, J ;
Shepherd, J .
BRITISH MEDICAL JOURNAL, 1997, 315 (7122) :1577-1582
[9]   SURVIVAL AS AN INDEX OF ADEQUACY OF DIALYSIS [J].
CHARRA, B ;
CALEMARD, E ;
RUFFET, M ;
CHAZOT, C ;
TERRAT, JC ;
VANEL, T ;
LAURENT, G .
KIDNEY INTERNATIONAL, 1992, 41 (05) :1286-1291
[10]   Cost-effectiveness of cancer screening in end-stage renal disease [J].
Chertow, GM ;
Paltiel, AD ;
Owen, WF ;
Lazarus, JM .
ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (12) :1345-1350